Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 366

It watches, saps the very spirit. And the worst thing of all is I watch it. I can’t not look. It’s like a drug, a horrible drug. You can’t resist it. It’s an addiction. These words of testimony are babbled by the crumbling Colonel Grover to describe O.B.I.T. — The Outer Band Individuated Teletracer — a hellishly precise surveillance machine of questionable origin. Uncovered by a murder investigation at a Defense Department research center, O.B.I.T. proves to be an insidious instrument that breeds fear and hostility. Both cautionary tale and tight courtroom drama, this haunting episode explores the fear and hostility that result when all privacy is eliminated…and all secrets are revealed! Alan Baxter, Jeff Corey and Peter Breck star!

Read more | >

Using electromagnetic fields or implanted medical devices to stimulate the brain can have benefits, but also carries risks. Computer simulations that reflect the unique complexity of each patient can help predict and solve problems before they arise.

Read more | >

People with advanced neuroendocrine tumors in the digestive system may benefit from a treatment combination that includes the drug Lu 177-dotatate (Lutathera), according to the results of a first-of-its-kind clinical trial.

All participants in the trial, called NETTER-2, had advanced neuroendocrine tumors in the gastrointestinal tract or pancreas that had not yet been treated.

Those who received Lu 177-dotatate plus octreotide (Sandostatin) lived almost three times as long without their cancer getting worse (progression-free survival) as those who received octreotide alone—a median of nearly 23 months, versus 8.5 months. And the number of people whose tumors shrank, sometimes completely, was nearly five times greater in those who received both drugs compared to those who only received octreotide.

Read more | >

Post-mitotic neurons in the brain that re-enter the cell cycle quickly succumb to senescence, and this re-entry is more common in Alzheimer’s disease, according to a new study published April 9 in the open-access journal PLOS Biology by Kim Hai-Man Chow and colleagues at the Chinese University of Hong Kong.

The phenomenon may provide an opportunity to learn more about the neurodegeneration process, and the technique used to make this discovery is readily applicable to other inquiries about unique populations of cells in the brain.

Most neurons in the brain are post-mitotic, meaning they have ceased to divide. For many years, it had been assumed that this post-mitotic state was permanent. Recent discoveries have shown that a small proportion of neurons re-enter the cell cycle, but little is known about their fate after they do.

Read more | >

The researchers said the current design of the FRS means multiple cardiovascular conditions are overlooked and consequently under-diagnosed in women.

“When it comes to cardiovascular diseases in particular, the prevalence of these diseases is higher in men than women, but several studies have shown that women are less likely to be diagnosed during a routine exam, get diagnosed at an older age, and with more severe symptoms than men,” Skyler St. Pierre, a study author and a researcher at the Stanford University Living Matter Lab in California, told Medical News Today. “This really points to the fact that we are under-diagnosing women and the current screening methods are not catching women with cardiovascular diseases early enough.”

Read more | >

Thsi is a year old. But at 27 minutes David gets asked a couple fo “when” questions.

Dr. David Sinclair presents the progress of epigenetic reprogramming and rejuvenation in this video. He’s also answering questions on when he thinks the rejuvenation therapy be available in the Q\&A session at the end of the presentation.

00:54 Presentation.
25:42 Q\&A

David Sinclair is a professor in the Department of Genetics and co-director of the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School, where he and his colleagues study sirtuins—protein-modifying enzymes that respond to changing NAD+ levels and to caloric restriction—as well as chromatin, energy metabolism, mitochondria, learning and memory, neurodegeneration, cancer, and cellular reprogramming.

Dr David Sinclair has suggested that aging is a disease—and that we may soon have the tools to put it into remission—and he has called for greater international attention to the social, economic and political and benefits of a world in which billions of people can live much longer and much healthier lives.

Continue reading “Will Rejuvenation Therapy Be Available In Our LIFETIME? Gene Therapy VS Small Molecules” | >

Years ago, a man paralyzed in a surfing accident was able to walk again after undergoing a revolutionary stem cell treatment. Now, he says that his mobility has only continued to improve! Chris Barr was one out of only 10 people to undergo this experimental treatment in a study by the Mayo Clinic. It’s safe to say that the procedure was a success for this patient!

“I never dreamed I would have a recovery like this,” Chris said, according to Good Morning America.

Before receiving care, Chris was paralyzed from the neck down, making it unlikely that he would ever walk again. However, a new stem cell treatment from the Mayo Clinic offered hope. He would be the first to try it, with incredible results.

Read more | >

Human history was forever changed with the discovery of antibiotics in 1928. Infectious diseases such as pneumonia, tuberculosis and sepsis were widespread and lethal until penicillin made them treatable.

Surgical procedures that once came with a high risk of infection became safer and more routine. Antibiotics marked a triumphant moment in science that transformed medical practice and saved countless lives.

But antibiotics have an inherent caveat: When overused, bacteria can evolve resistance to these drugs. The World Health Organization estimated that these superbugs caused 1.27 million deaths around the world in 2019 and will likely become an increasing threat to global public health in the coming years.

Read more | >

Jason Matheny is a delight to speak with, provided you’re up for a lengthy conversation about potential technological and biomedical catastrophe.

Now CEO and president of Rand Corporation, Matheny has built a career out of thinking about such gloomy scenarios. An economist by training with a focus on public health, he dived into the worlds of pharmaceutical development and cultivated meat before turning his attention to national security.

As director of Intelligence Advanced Research Projects Activity, the US intelligence community’s research agency, he pushed for more attention to the dangers of biological weapons and badly designed artificial intelligence. In 2021, Matheny was tapped to be President Biden’s senior adviser on technology and national security issues. And then, in July of last year, he became CEO and president of Rand, the oldest nonprofit think tank in the US, which has shaped government policy on nuclear strategy, the Vietnam War, and the development of the internet.

Read more | >